George Tidmarsh has only been at the Center for Drug Evaluation and Research for nine days, but will now add supervision of a ...

As analysts parsed news of Vinay Prasad’s ouster, worries over drug approval delays, cell and gene therapy impacts and more ...

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for ...

CEO Emma Walmsley maintained that continued investment in the U.S. is a priority for the pharma to ensure its medicines for ...

Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Susan Monarez is the first CDC director to be confirmed by the Senate under a new 2023 law and will be the first person ...

Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price ...

The FDA’s dramatic summer continues to unfold as news broke late Tuesday evening that Vinay Prasad will depart the agency, ...

Though nerves abound for funders and founders in the industry, money continues to flow into startups, sometimes in ...

Sarepta’s Elevidys is back on the market for ambulatory patients with Duchenne muscular dystrophy, Health Secretary Robert F. Kennedy Jr. reportedly plans to dissolve the U.S. Preventive Services Task ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...